Classics in Neuroimaging: Imaging the Endocannabinoid Pathway with PET.
Cassis VarlowIsabelle BoileauHsiao-Ying WeySteven H LiangNeil VasdevPublished in: ACS chemical neuroscience (2020)
This Viewpoint aims to highlight positron emission tomography (PET) research studies that have shaped our understanding of the endocannabinoid system (ECS) through radiopharmaceutical targeting of cannabinoid receptors 1 and 2 (CB1 and CB2), and the enzyme fatty acid amide hydrolase (FAAH), in several brain health illnesses including addiction, schizophrenia, eating disorders, and post-traumatic stress disorder. Advances in radiochemistry, including 11C-carbonylation and radiofluorination of nonactivated aromatic rings, are accelerating the translation of radiotracers with optimal kinetics, bringing us closer to clinical PET research studies to image the enzyme monoacylglycerol lipase (MAGL) and enabling the imaging of unexplored targets in the ECS.
Keyphrases
- positron emission tomography
- computed tomography
- pet ct
- pet imaging
- high resolution
- fatty acid
- healthcare
- bipolar disorder
- case control
- public health
- mental health
- resting state
- deep learning
- functional connectivity
- depressive symptoms
- risk assessment
- mass spectrometry
- health promotion
- climate change
- social media
- health information
- human health